News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to 16.6% weight loss with survodutide, a novel glucagon/GLP ...
Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat ...
YouTube on MSN
Peptides: What you need to know (Dr Nick Norwitz MD PhD)
“What Are Your Thoughts on Peptides?” I can’t tell you how many times I’ve been asked that question lately. Over and over ...
Opinion
The Business & Financial Times on MSNOpinion
The anchor without the money: What Ghana should — and should not — expect from its new IMF arrangement
The empirical case that the Policy Coordination Instrument is a credibility tool, not a growth engine — and why judging it by the wrong yardstick will mislead the national conversation.By Dr Stephen ...
ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, including reductions in body weight and fat mass, ...
ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, including reductions in body weight and fat mass, improved insulin sensitivity, enhanced adipose function, ...
Stonehenge has always invited big questions, but one of its most stubborn mysteries sits low to the ground. The Altar Stone, ...
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...
Phase III ALIGN study results showed reduced rate of kidney function decline by ~34% with Vanrafia vs placebo, based on ...
Analyses demonstrate consistent positive signals across endpoints in AKI patientsFindings derived from post hoc analysis of 101 patients also experiencing respiratory distressNew data and analysis to ...
A clinical trial is underway at La Trobe University and its Athens counterpart for an Australian-made probiotic, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results